| First Author | Garton FC | Year | 2018 |
| Journal | Am J Hum Genet | Volume | 102 |
| Issue | 5 | Pages | 845-857 |
| PubMed ID | 29706347 | Mgi Jnum | J:269275 |
| Mgi Id | MGI:6272206 | Doi | 10.1016/j.ajhg.2018.03.009 |
| Citation | Garton FC, et al. (2018) The Effect of ACTN3 Gene Doping on Skeletal Muscle Performance. Am J Hum Genet 102(5):845-857 |
| abstractText | Loss of expression of ACTN3, due to homozygosity of the common null polymorphism (p.Arg577X), is underrepresented in elite sprint/power athletes and has been associated with reduced muscle mass and strength in humans and mice. To investigate ACTN3 gene dosage in performance and whether expression could enhance muscle force, we performed meta-analysis and expression studies. Our general meta-analysis using a Bayesian random effects model in elite sprint/power athlete cohorts demonstrated a consistent homozygous-group effect across studies (per allele OR = 1.4, 95% CI 1.3-1.6) but substantial heterogeneity in heterozygotes. In mouse muscle, rAAV-mediated gene transfer overexpressed and rescued alpha-actinin-3 expression. Contrary to expectation, in vivo "doping" of ACTN3 at low to moderate doses demonstrated an absence of any change in function. At high doses, ACTN3 is toxic and detrimental to force generation, to demonstrate gene doping with supposedly performance-enhancing isoforms of sarcomeric proteins can be detrimental for muscle function. Restoration of alpha-actinin-3 did not enhance muscle mass but highlighted the primary role of alpha-actinin-3 in modulating muscle metabolism with altered fatiguability. This is the first study to express a Z-disk protein in healthy skeletal muscle and measure the in vivo effect. The sensitive balance of the sarcomeric proteins and muscle function has relevant implications in areas of gene doping in performance and therapy for neuromuscular disease. |
